Progesterone produces antinociceptive and neuroprotective effects in rats with microinjected lysophosphatidic acid in the trigeminal nerve root

Molecular Pain

Volumn 8, Issue , 2012, Pages

  Kim, Min J ^a   Shin, Hea J ^a   Won, Kyoung A ^a   Yang, Kui Y ^a   Ju, Jin S ^a   Park, Yoon Y ^b   Park, Jae S ^c   Bae, Yong C ^a   Ahn, Dong K ^a  

^a Kyungpook National University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Antinociception; LPA; Neuroprotection; Progesterone; Trigeminal neuralgia

Indexed keywords

LYSOPHOSPHATIDIC ACID; PERIPHERAL MYELIN PROTEIN 22; PROGESTERONE; PROTEIN; PROTEIN ZERO; UNCLASSIFIED DRUG; ANALGESIC AGENT; LYSOPHOSPHOLIPID; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DOWN REGULATION; MALE; MICROINJECTION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; STEREOTACTIC PROCEDURE; STIMULUS RESPONSE; TREATMENT DURATION; TRIGEMINAL NERVE; TRIGEMINAL NERVE INJURY; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; HYPERALGESIA; PATHOLOGY;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; HYPERALGESIA; LYSOPHOSPHOLIPIDS; MALE; MICROINJECTIONS; NEUROPROTECTIVE AGENTS; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; TRIGEMINAL NERVE;

EID: 84858329148     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-8-16     Document Type: Article

References (55)

1. Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD, Miller VM. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000, 31:161-168. 10.1161/01.STR.31.1.161, 10625733.
2. Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol 1994, 129:64-69. 10.1006/exnr.1994.1147, 7925843.
3. Roof RL, Duvdevani R, Heyburn JW, Stein DG. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol 1996, 138:246-251. 10.1006/exnr.1996.0063, 8620923.
4. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002, 178:59-67. 10.1006/exnr.2002.8020, 12460608.
5. Azcoitia I, Leonelli E, Magnaghi V, Veiga S, Garcia-Segura LM, Melcangi RC. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol Aging 2003, 24:853-860. 10.1016/S0197-4580(02)00234-8, 12927767.
6. Leonelli E, Bianchi R, Cavaletti G, Caruso D, Crippa D, Garcia-Segura LM, Lauria G, Magnaghi V, Roglio I, Melcangi RC. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007, 144:1293-1304. 10.1016/j.neuroscience.2006.11.014, 17187935.
7. Melcangi RC, Garcia-Segura LM. Therapeutic approaches to peripheral neuropathy based on neuroactive steroids. Expert Rev Neurother 2006, 6:1121-1125. 10.1586/14737175.6.8.1121, 16893339.
8. Roglio I, Bianchi R, Giatti S, Cavaletti G, Caruso D, Scurati S, Crippa D, Garcia-Segura LM, Camozzi F, Lauria G, Melcangi RC. Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. Cell Mol Life Sci 2007, 64:1158-1168. 10.1007/s00018-007-7002-5, 17417742.
9. Roglio I, Giatti S, Pesaresi M, Bianchi R, Cavaletti G, Lauria G, Garcia-Segura LM, Melcangi RC. Neuroactive steroids and peripheral neuropathy. Brain Res Rev 2008, 57:460-469. 10.1016/j.brainresrev.2007.04.010, 17543391.
10. Sereda MW, Meyer-zu-Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003, 9:1533-1537. 10.1038/nm957, 14608378.
11. Cervantes M, González-Vidal MD, Ruelas R, Escobar A, Moralí G. Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus. Arch Med Res 2002, 33:6-14. 10.1016/S0188-4409(01)00347-2, 11825624.
12. Chen J, Chopp M, Li Y. Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat. J Neurol Sci 1999, 171:24-30. 10.1016/S0022-510X(99)00247-6, 10567046.
13. Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res 1996, 735:101-107. 10.1016/0006-8993(96)00605-1, 8905174.
14. Kumon Y, Kim SC, Tompkins P, Stevens A, Sakaki S, Loftus CM. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg 2000, 92:848-852. 10.3171/jns.2000.92.5.0848, 10794300.
15. Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999, 24:2134-2138. 10.1097/00007632-199910150-00013, 10543012.
16. Coronel MF, Labombarda F, Villar MJ, De Nicola AF, González SL. Progesterone prevents allodynia after experimental spinal cord injury. J Pain 2011, 12:71-83. 10.1016/j.jpain.2010.04.013, 20675200.
17. Kondo D, Yabe R, Kurihara T, Saegusa H, Zong S, Tanabe T. Progesterone receptor antagonist is effective in relieving neuropathic pain. Eur J Pharmacol 2006, 541:44-48. 10.1016/j.ejphar.2006.05.010, 16759651.
18. Gardner WJ. Concerning the mechanism of trigeminal neuralgia and hemifacial spasm. J Neurosurg 1962, 19:947-958. 10.3171/jns.1962.19.11.0947, 13946557.
19. Jannetta PJ. Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia. J Neurosurg 1967, 26(Suppl):159-162.
20. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain 2001, 124:2347-2360. 10.1093/brain/124.12.2347, 11701590.
21. Hilton DA, Love S, Gradidge T, Coakham HB. Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery 1994, 35:299-303. 10.1227/00006123-199408000-00017, 7969838.
22. Pages C, Simon M, Valet P, Saulnier-Blache JS. Lysophosphatidic acid synthesis and release (1). Prostaglandins 2001, 64:1-10.
23. Swartley JS, Balthazar JT, Coleman J, Shafer WM, Stephens DS. Membrane glycerophospholipid biosynthesis in Neisseria meningitidis and Neisseria gonorrhoeae: identification, characterization, and mutagenesis of a lysophosphatidic acid acyltransferase. Mol Microbiol 1995, 18:401-412. 10.1111/j.1365-2958.1995.mmi_18030401.x, 8748025.
24. An S, Goetzl EJ, Lee H. Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J Cell Biochem Suppl 1998, 30-31:147-157.
25. Moolenaar WH, Kranenburg O, Postma FR, Zondag GC. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 1997, 9:168-173. 10.1016/S0955-0674(97)80059-2, 9069262.
26. Pietruck F, Busch S, Virchow S, Brockmeyer N, Siffert W. Signalling properties of lysophosphatidic acid in primary human skin fibroblasts: role of pertussis toxin-sensitive GTP-binding proteins. Naunyn Schmiedebergs Arch Pharmacol 1997, 355:1-7.
27. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10:712-718. 10.1038/nm1060, 15195086.
28. Nagai J, Uchida H, Matsushita Y, Yano R, Ueda M, Niwa M, Aoki J, Chun J, Ueda H. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol Pain 2010, 6:78. 10.1186/1744-8069-6-78, 2989310, 21062487.
29. Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006, 109:57-77. 10.1016/j.pharmthera.2005.06.003, 16023729.
30. Inoue M, Ma L, Aoki J, Chun J, Ueda H. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 2008, 4:6. 10.1186/1744-8069-4-6, 2277392, 18261210.
31. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK, Youn DH, Bae YC. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009, 146:114-120. 10.1016/j.pain.2009.07.012, 19665300.
32. Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. J Neurosurg 2002, 96:532-543. 10.3171/jns.2002.96.3.0532, 11883839.
33. De Nicola AF, Gonzalez SL, Labombarda F, Deniselle MC, Garay L, Guennoun R, Schumacher M. Progesterone treatment of spinal cord injury: effects on receptors, neurotrophins, and myelination. J Mol Neurosci 2006, 28:3-15. 10.1385/JMN:28:1:3, 16632872.
34. Garay L, Deniselle MC, Meyer M, Costa JJ, Lima A, Roig P, De nicola AF. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune ncephalomyelitis. Brain Res 2009, 1283:177-185.
35. Gonzalez-Deniselle MC, Garay L, Gonzalez S, Saravia F, Labombarda F, Guennoun R, Schumacher M, De Nicola AF. Progesterone modulates brain-derived neurotrophic factor and choline acetyltransferase in degenerating Wobbler motoneurons. Exp Neurol 2007, 203:406-414. 10.1016/j.expneurol.2006.08.019, 17052708.
36. Notterpek L, Snipes GJ, Shooter EM. Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination. GLIA 1999, 25:358-369. 10.1002/(SICI)1098-1136(19990215)25:4<358::AID-GLIA5>3.0.CO;2-K, 10028918.
37. Desarnaud F, Do Thi AN, Brown AM, Lemke G, Suter U, Baulieu EE, Schumacher M. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J Neuroche 1998, 71:1765-1768.
38. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ, Nilsen J. Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008, 29:313-339. 10.1016/j.yfrne.2008.02.001, 2398769, 18374402.
39. Chan JR, Phillips LJ, Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc Natl Acad Sci USA 1998, 95:10459-10464. 10.1073/pnas.95.18.10459, 27916, 9724725.
40. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007, 116:77-106. 10.1016/j.pharmthera.2007.06.001, 17659348.
41. Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev 2008, 57:386-397. 10.1016/j.brainresrev.2007.06.012, 2699575, 17826842.
42. Schumacher M, Sitruk-Ware R, De Nicola AF. Progesterone and progestins: neuroprotection and myelin repair. Curr Opin Pharmacol 2008, 8:740-746. 10.1016/j.coph.2008.10.002, 18929681.
43. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW. Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002, 57:339-355. 10.1210/rp.57.1.339, 12017551.
44. Magnaghi V, Cavarretta I, Galbiati M, Martini L, Melcangi RC. Neuroactive steroids and peripheral myelin proteins. Brain Res Brain Res Rev 2001, 37:360-371.
45. Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG. The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol Dis 2008, 30:30-41. 10.1016/j.nbd.2007.12.001, 18291663.
46. Patte-Mensah C, Li S, Mensah-Nyagan AG. Impact of neuropathic pain on the gene expression and activity of cytochrome P450side-chain-cleavage in sensory neural networks. Cell Mol Life Sci 2004, 61:2274-2284.
47. Patte-Mensah C, Penning TM, Mensah-Nyagan AG. Anatomical and cellular localization of neuroactive 5 alpha/3 alpha-reduced steroid-synthesizing enzymes in the spinal cord. J Comp Neurol 2004, 477:286-299. 10.1002/cne.20251, 15305365.
48. Orsal AS, Blois S, Labuz D, Peters EM, Schaefer M, Arck PC. The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. J Mol Med 2006, 84:159-167. 10.1007/s00109-005-0005-5, 16389545.
49. Ahn DK, Kim KH, Jung CY, Choi HS, Lim EJ, Youn DH, Bae YC. Role of peripheral group I and II metabotropic glutamate receptors in IL-1beta-induced mechanical allodynia in the orofacial area of conscious rats. Pain 2005, 118:53-60. 10.1016/j.pain.2005.07.017, 16154694.
50. Ahn DK, Lim EJ, Kim BC, Yang GY, Lee MK, Ju JS, Han SR, Bae YC. Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats. Eur J Pain 2009, 13:568-575. 10.1016/j.ejpain.2008.07.008, 18774318.
51. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J Neurosci 1994, 14:2708-2723.
52. Park CK, Kim K, Jung SJ, Kim MJ, Ahn DK, Hong SD, Kim JS, Oh SB. Molecular mechanism for local anesthetic action of eugenol in the rat trigeminal system. Pain 2009, 144:84-94. 10.1016/j.pain.2009.03.016, 19376653.
53. Goss CW, Hoffman SW, Stein DG. Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol Biochem Behav 2003, 76:231-242. 10.1016/j.pbb.2003.07.003, 14592674.
54. Ahn DK, Choi HS, Yeo SP, Woo YW, Lee MK, Yang GY, Jeon HJ, Park JS, Mokha SS. Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 2007, 132:23-32. 10.1016/j.pain.2007.01.015, 17321048.
55. Erichsen HK, Hao JX, Xu XJ, Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain 2005, 116:347-358. 10.1016/j.pain.2005.05.004, 15982817.